[go: up one dir, main page]

FI4233847T3 - Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti - Google Patents

Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti Download PDF

Info

Publication number
FI4233847T3
FI4233847T3 FIEP23172275.2T FI23172275T FI4233847T3 FI 4233847 T3 FI4233847 T3 FI 4233847T3 FI 23172275 T FI23172275 T FI 23172275T FI 4233847 T3 FI4233847 T3 FI 4233847T3
Authority
FI
Finland
Prior art keywords
tablet according
methoxyurea
tetrahydrothieno
difluorobenzyl
dioxo
Prior art date
Application number
FIEP23172275.2T
Other languages
English (en)
Finnish (fi)
Inventor
Ikuro Yamane
Yukihiro Nomura
Yutaka Nishimoto
Wataru Hoshina
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56789547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4233847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of FI4233847T3 publication Critical patent/FI4233847T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP23172275.2T 2015-02-26 2016-02-25 Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti FI4233847T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015037462 2015-02-26

Publications (1)

Publication Number Publication Date
FI4233847T3 true FI4233847T3 (fi) 2024-09-24

Family

ID=56789547

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP23172275.2T FI4233847T3 (fi) 2015-02-26 2016-02-25 Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti
FIEP16755593.7T FI3263110T3 (fi) 2015-02-26 2016-02-25 Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP16755593.7T FI3263110T3 (fi) 2015-02-26 2016-02-25 Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita

Country Status (24)

Country Link
US (2) US10350170B2 (fr)
EP (3) EP4454708A3 (fr)
JP (1) JP6730978B2 (fr)
CN (1) CN107249590A (fr)
AU (1) AU2016224503B2 (fr)
BR (1) BR112017018173A2 (fr)
CA (1) CA2978223A1 (fr)
CY (1) CY1126118T1 (fr)
DK (2) DK4233847T3 (fr)
ES (2) ES2950995T3 (fr)
FI (2) FI4233847T3 (fr)
HR (1) HRP20230613T1 (fr)
HU (1) HUE062269T2 (fr)
IL (1) IL254132B (fr)
LT (1) LT3263110T (fr)
MX (1) MX373225B (fr)
MY (1) MY180680A (fr)
PL (2) PL4233847T3 (fr)
PT (1) PT3263110T (fr)
RS (1) RS64377B1 (fr)
SI (2) SI4233847T1 (fr)
SM (1) SMT202300221T1 (fr)
TW (1) TWI744224B (fr)
WO (1) WO2016136849A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119564A1 (fr) 2012-09-28 2023-01-18 Takeda Pharmaceutical Company Limited Procédé de production de dérivés de thiénopyridine
HRP20241740T1 (hr) 2016-09-30 2025-02-28 Sumitomo Pharma Switzerland Gmbh Liječenje raka prostate
HUE072130T2 (hu) 2016-09-30 2025-10-28 Sumitomo Pharma Switzerland Gmbh Orális rögzített dózisú kombináció és annak felhasználása méhmióma és endometriosis kezelésében
TW201912157A (zh) 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
EP3668515A4 (fr) 2017-08-18 2021-05-12 Abbvie Inc. Formulations pharmaceutiques pour le traitement de l'endométriose, de fibromes utérins, du syndrome des ovaires polykystiques ou de l'adénomyose
EP3765464A1 (fr) 2018-03-14 2021-01-20 Teva Pharmaceuticals USA, Inc. Formes à l'état solide de relugolix
CA3145993A1 (fr) 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Formes a l'etat solide de relugolix
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
JP7029875B1 (ja) 2020-05-15 2022-03-04 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物
WO2021239917A1 (fr) * 2020-05-29 2021-12-02 Myovant Sciences Gmbh Formes posologiques orales solides combinées d'antagonistes de l'hormone de libération de la gonadotropine
JP2023549196A (ja) 2020-11-11 2023-11-22 ミオバント サイエンシズ ゲーエムベーハー レルゴリクスの投与方法
EP4419530A1 (fr) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Forme cristalline d'un solvate d'éthanol de n-(4-(1-(2,6-difluorobenzyle)-5-((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl)phényle)-n'-méthoxyurée
CN115671069A (zh) * 2022-11-24 2023-02-03 北京鑫开元医药科技有限公司 一种瑞卢戈利片剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW284688B (fr) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
FR2710637B1 (fr) * 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3854648B2 (ja) * 1994-04-19 2006-12-06 武田薬品工業株式会社 縮合チオフェン誘導体、その製造法及び用途
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
WO2003064429A1 (fr) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
JP5072166B2 (ja) * 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
US20050163835A1 (en) * 2002-02-26 2005-07-28 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
CA2514407C (fr) 2003-01-29 2012-01-03 Takeda Pharmaceutical Company Limited Composes de thienopyrimidine et utilisation
JP4039574B2 (ja) * 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
JP2006035365A (ja) * 2004-07-26 2006-02-09 Hitachi Koki Co Ltd 携帯用切断工具
JPWO2010026993A1 (ja) * 2008-09-03 2012-02-02 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
JP2015037462A (ja) 2012-06-01 2015-02-26 株式会社コナミデジタルエンタテインメント ゲーム装置、ゲーム方法、及びプログラム
EP4119564A1 (fr) 2012-09-28 2023-01-18 Takeda Pharmaceutical Company Limited Procédé de production de dérivés de thiénopyridine
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Also Published As

Publication number Publication date
BR112017018173A2 (pt) 2018-04-10
US10350170B2 (en) 2019-07-16
CY1126118T1 (el) 2023-11-15
SMT202300221T1 (it) 2023-09-06
PL3263110T3 (pl) 2023-11-06
ES2988678T3 (es) 2024-11-21
AU2016224503A1 (en) 2017-09-14
MX2017010945A (es) 2018-07-06
TWI744224B (zh) 2021-11-01
RS64377B1 (sr) 2023-08-31
SI4233847T1 (sl) 2025-02-28
MY180680A (en) 2020-12-06
DK3263110T3 (da) 2023-07-31
PT3263110T (pt) 2023-08-01
JPWO2016136849A1 (ja) 2017-12-07
AU2016224503B2 (en) 2021-07-08
EP3263110A4 (fr) 2018-11-07
ES2950995T3 (es) 2023-10-17
EP3263110A1 (fr) 2018-01-03
EP4233847B1 (fr) 2024-07-10
CA2978223A1 (fr) 2016-09-01
EP4233847A1 (fr) 2023-08-30
CN107249590A (zh) 2017-10-13
EP3263110B1 (fr) 2023-05-10
MX373225B (es) 2020-04-08
EP4454708A3 (fr) 2024-11-13
HUE062269T2 (hu) 2023-10-28
NZ735026A (en) 2021-09-24
TW201639575A (zh) 2016-11-16
US20200000730A1 (en) 2020-01-02
DK4233847T3 (da) 2024-09-30
US20180036250A1 (en) 2018-02-08
WO2016136849A1 (fr) 2016-09-01
PL4233847T3 (pl) 2024-11-18
HRP20230613T1 (hr) 2023-09-29
SI3263110T1 (sl) 2023-09-29
IL254132B (en) 2020-02-27
EP4454708A2 (fr) 2024-10-30
JP6730978B2 (ja) 2020-07-29
FI3263110T3 (fi) 2023-07-25
IL254132A0 (en) 2017-10-31
LT3263110T (lt) 2023-07-10

Similar Documents

Publication Publication Date Title
FI4233847T3 (fi) Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti
TWI354569B (en) Coated tablet formulation and method
ES2768349T3 (es) Preparación farmacéutica que comprende un derivado de fenilalanina
JP2018021082A5 (fr)
FI3150200T3 (fi) Menetelmä sglt-2-inhibiittorin ja metformiinin sisältävän tabletin valmistamiseksi
JP2015531365A5 (fr)
JP2009545560A5 (fr)
HRP20200037T4 (hr) TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL
JP2016531151A5 (fr)
EP2468361B1 (fr) Formulations de vildagliptine
WO2014030204A1 (fr) Particule creuse contenant un médicament
RU2011112362A (ru) Твердые препаративные формы оспемифена
JP7209555B2 (ja) ラメルテオン含有フィルムコーティング錠剤
RU2016102605A (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
JP6856326B2 (ja) 腸放出粒子組成物
US10258577B2 (en) Multilayer solid pharmaceutical dosage forms
WO2017029609A1 (fr) Composition pharmaceutique d'alogliptine et de metformine
JP2017520619A5 (fr)
JP2015221782A (ja) モンテルカストナトリウム含有製剤
JP2016069382A5 (fr)
RU2021116298A (ru) Аморфная твердая дисперсия, содержащая 6-(1-акрилоилпиперидин-4-ил)-2-(4-феноксифенил)никотинамид
JP2014224087A (ja) 光安定性が向上したテルミサルタン含有固形製剤
JP2004002460A (ja) 易吸収性ニルバジピン錠の製造法
Van Arnum Meeting solubility challenges
CZ2016256A3 (cs) Pevná farmaceutická léková forma obsahující gefitinib